Table 1 Comparison of baseline characteristics of patients infected with S. epidermidis isolates according to their teicoplanin-susceptibility.

From: Increased incidence of teicoplanin-non-susceptible Staphylococcus epidermidis strains: a 6-year retrospective study

Characteristic, N (%)

Teico-S groupa (n = 311)

Teico-NS groupb (n = 17)

P value

Demographics

 Age, median (IQR), years

68.0 (57.0–79.0)

77.0 (70.5–83.0)

0.01

 Male

187 (60.1)

9 (52.9)

0.62

Underlying disease

 Hypertension

165 (53.1)

8 (47.1)

0.63

 Diabetes mellitus

117 (37.6)

9 (52.9)

0.21

 Congestive heart disease

16 (5.1)

0

1.00

 Cerebrovascular accident

85 (27.3)

2 (11.8)

0.26

 Chronic liver disease

21 (6.8)

1 (5.9)

1.00

 Chronic kidney disease

29 (9.3)

1 (5.9)

1.00

 Solid cancer

55 (17.7)

1 (5.9)

0.32

 Hematological malignancy

4 (1.3)

1 (5.9)

0.24

COVID-19 infectionc

9 (2.9)

5 (29.4)

0.04

Previous antibiotic use

273 (87.8)

15 (88.2)

1.00

 Glycopeptide antibiotics

122 (39.2)

4 (23.5)

0.31

 Vancomycin

40 (12.9)

0 (0.0)

0.24

 Teicoplanin

101 (32.5)

4 (23.5)

0.60

Source of isolates

 Blood

236 (81.1)

15 (88.2)

0.36

Oxacillin-resistance

275 (88.4)

17 (100.0)

0.23

  1. Data are presented as the number of patients (with the corresponding percentage in parentheses) unless otherwise specified.
  2. Teico-S teicoplanin-susceptible, Teico-NS teicoplanin-non-susceptible, IQR interquartile range, MIC minimal inhibitory concentration.
  3. aTeicoplanin MIC values < 16 mg/L.
  4. bTeicoplanin MIC values ≥ 16 mg/L.
  5. cPatients infected with COVID-19 were only present in 2020 and 2021. (n = 6 and 8, respectively).
Back to article page